Toll Free : + 1-888-961-4454 | Int'l : + 91 (788) 802-9103 | support@researchdive.com
LI21098494 |
Pages: 210 |
May 2022 |
Increasing cases of neurological diseases such as epilepsy, Parkinson’s disease, and Alzheimer’s disease in all aged people, especially in geriatric population are expected to drive the market of neuromonitoring devices, globally. The rising incidence rates of neurological diseases, mind up of neurodegenerative disorders, a rise in the number of brain injuries, and recent expansion of brain tracking in clinical studies are going to drive the neuromonitoring devices market. Rising demand for non-invasive and nondestructive gadgets, expanding clinical uses of neuromonitoring devices, and the expanding healthcare market in emerging economies are all expected to provide opportunities for neuromonitoring devices market participants.
However, high cost of neuromonitoring devices and dearth of skilled technicians & personnel are expected to hinder the market growth. Moreover, a lack of qualified professionals for device performance and high due process costs associated with neuromonitoring devices deployment are expected to present a challenge to the market expansion of neuromonitoring devices all through the period of analysis.
According to the regional analysis of the market, the Asia-Pacific neuromonitoring devices market is anticipated to grow at a CAGR of 7.99%, by generating a revenue of $2,702.6 million during the review period.
Neuromonitoring devices are medical devices which are capable of displaying or monitoring the vital signs of patient’s brain, recording data such as electrical impulse rate, blood flow, & oxygen level, and instantly displaying the result. These devices are widely used in hospitals, clinics, and more. Various types of neuromonitoring devices are available in the market like doppler ultrasound, computed tomography (CT scan), and magnetic resonance imaging (MRI).
The COVID-19 pandemic has severely affected the business sector, across the world. During the pandemic, where healthcare sector experienced a positive growth, neuromonitoring devices market experienced a major setback due to decreased demand in the hospitals and clinics. Since corona virus is highly transmissible and spreads rapidly in the environment, affecting many people in the minimum time, the hospital authorities restricted the admission of patients with other diseases and this factor has decreased the demand for neuromonitoring devices. Also, many neurosurgeries were postponed amid rising cases of corona virus patients. This factor is further likely to impede the market growth in the pandemic duration.
Moreover, need for remote monitoring and patient management solutions has soared significantly as a result of the outbreak's urgency. Majority health care facilities have been presently trying to expand monitoring of patients to home care or other momentary configurations in order to provide the best possible care. In comparison to neuromonitoring devices, COVID-19 has resulted in a significant increase in supply for ventilators, and industries are continuously focusing their attention to meet the ever increasing for ventilators, including the other diagnostic devices. The pandemic is considered to have a negative impact on the neuromonitoring devices industry, due to hospital systems' aim of establishing COVID-19 specific ICUs, and the temporary ban of industrial and assembly sites throughout major cities.
Rapidly increasing neurological diseases like dementia and epilepsy among old age population are expected to accelerate the neuromonitoring devices market, globally. Also, increased rate of hospitalizations and emergency department admissions owing to serious health conditions and brain injury due to road accidents is further expected to increase the market revenue of neuromonitoring devices.
Moreover every day, the number of neurological illnesses and catastrophic accidents grows. Neurological illnesses, seizures, Parkinson's, strokes, multiple sclerosis, and headaches affected roughly 1 billion individuals, or 1 in every five or six people in the world, as according to UN data from 2007. The market for neuromonitoring devices is being driven by an increase in the number of people suffering from neurological illnesses. Furthermore, the Centers for Disease Control and Prevention estimated that 2.5 million traumatic accidents occur in the United States each year, resulting in brain infection, meningitis, and aneurysm. This necessitates intracranial pressure monitoring, which drives the growth of neuromonitoring devices market.
Apart from this, introduction of wearable neuromonitoring devices to avoid unnecessary visits and hospitalizations is further expected to drive the market of neuromonitoring devices in the forecast time period. Wearable neuromonitoring devices are important tools to regularly monitor brain health while patients are at home or while traveling. For instance, according to a news published on Med Tech Innovations, technology news portal, on May 14, 2021, WISE Srl, a medical device manufacturing company, developed its WISE Cortical Strip (WCS). It is a single use medical device which is attached on the brain surface for intraoperative neurophysiological monitoring (IONM). Such factors are likely to flourish the market growth in the forecast time frame.
To know more about global neuromonitoring devices market drivers, get in touch with our analysts here.
Neuromonitoring devices are very expensive and can be opted at a mode of treatment only by the patients who can afford costly treatment. This factor restrains the market from growth. Furthermore, due to high cost of the devices, not many healthcare facilities like small hospitals & clinics in rural areas can afford to keep these expensive devices for patient’s treatment. The high price of neuromonitoring surgeries and devices is a key restraint on the global industry, especially in underdeveloped countries with lax reimbursement rules. Neuromonitoring technologies are extremely complicated, and the procedures requiring their utilization are often costly. For example, the average cost of neuromonitor is around USD 340–500, with dual computed tomography costs around USD 3,000–3,200. All such factors are expected to restrain the market growth.
According to WHO data, approximately 50 million people in world are affected by dementia as of September 2019, with nearly 10 million cases registered each year. This is one of the main causes of disability or reliance among aged all around globe. According to WHO estimates, around 50 million people worldwide suffered with epilepsy in June 2019, with nearly 80% living in low and middle-income countries. Epilepsy is predicted to affect 150,000 people in the United States each year, or 48 people for every 100,000 people (Source: Epilepsy Foundation). Epilepsy affects around 3.4 million people in the United States.
Technological advancements in the development of neuromonitoring devices to monitor the brain health of the patients are expected to accelerate the market growth in the future. Amid rising demand for advanced neuromonitoring devices, the manufacturing companies have started investing a huge amount in pacing their research and development activities which has boosted the market growth further. For instance, according to a news published on Business Wire, online news portal, on February 23, 2021, Rhythmlink International, LLC, a company that manufactures medical devices, announced FDA clearance of its new product line called sticky pad surface electrodes. The new device is stick-on electrodes that is used for intraoperative neurophysiological monitoring (IONM) and electroencephalography (EEG). Such advancements are likely to accelerate the market growth of neuromonitoring devices in the future.
To know more about global neuromonitoring devices s market opportunities, get in touch with our analysts here.
Based on product, the global neuromonitoring devices market is segmented into intracranial pressure monitoring, cerebral oximeter, near infrared spectroscopy, speckle imaging, doppler ultrasound, EEG, fetal/neonatal neuromonitoring devices, micro ultrasound, and others. Doppler ultrasound sub-segment is projected to generate the maximum revenue and near infrared spectroscopy sub-segment is predicted to show the fastest growth.
Source: Research Dive Analysis
The doppler ultrasound sub-segment is predicted to have a dominating market share in the global market and register a revenue of $3,153.5 million during the forecast period. Doppler ultrasounds employ sound waves to create images of how blood flows through veins and arteries in the body. Often, the purpose is to check blood flow in the arms and legs. A handheld instrument creates sound waves that bounce off moving things like blood cells during a doppler ultrasonography. The reflected sound waves generate a representation of blood flow. The growth is attributed to increasing cases of neurological disorders among people of all age group, especially geriatric population. Doppler ultrasound is a popular imaging test that is used to observe proper blood flow through veins and arteries in the patient’s body. The test is conducted by using sound waves which detect blood movements through blood vessels. Doppler ultrasound is widely used for observing brain health in cases of severe accidents. It is also used to detect any blood clot present inside the brain. Such advantages of the technique is expected to drive the market of neuromonitoring devices in the forecast time period.
The neuromonitoring devices market was investigated across North America, Europe, Asia-Pacific, and LAMEA.
Source: Research Dive Analysis
The North America neuromonitoring devices market accounted $1,996.7 million in 2021 and is projected to register a revenue of $3,534.9 million by 2030. The growth is attributed to the rising demand for better and advanced healthcare facilities among patients. Also, adoption of new and advanced technologies might further increase the market revenue of North America. Major market players have focused on launching new products in the market to cater the rising demand for neuromonitoring devices amid rising cases of neurological disorders such as epilepsy. Apart from this, prevalence of neurological disorders in the North America region is anticipated to drive the market even further. In 2021, North America dominated the market, accounting for approximately 49.30%of worldwide sales. This dominance is mostly due to advantageous reimbursement conditions and an increase in the number of instances of neurological illnesses. According to the National Institute of Health, roughly 795,000 people in the United States have a stroke each year, resulting in 137,000 deaths. Furthermore, the Migraine Research Foundation estimated that 35 million Americans would suffer from migraine headaches by 2020. Furthermore, migraines are predicted to affect approximately 43% of women and 18% of males in the country. As a result, rising incidences of neurological illnesses like TBI, migraine, and stroke are expected to fuel market growth in this country.
Source: Research Dive Analysis
The companies involved in the neuromonitoring devices market are GE Healthcare, Koninklijke Philips N.V., Medtronic Plc, Nihon Kohden Corporation, Natus Medical Incorporated., Nuvasive, Inc., Advanced Brain Monitoring, Inc., Intranerve Neuroscience Holdings, Llc, Specialtycare, and RIMED Ltd.
Aspect | Particulars |
Historical Market Estimations | 2020-2021 |
Base Year for Market Estimation | 2021 |
Forecast Timeline for Market Projection | 2021-2030 |
Geographical Scope | North America, Europe, Asia-Pacific, LAMEA |
Segmentation by Product |
|
Key Companies Profiled |
|
1.Research Methodology
1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters
1.5.Market size estimation
1.5.1.Top-down approach
1.5.2.Bottom-up approach
2.Report Scope
2.1.Market definition
2.2.Key objectives of the study
2.3.Report overview
2.4.Market segmentation
2.5.Overview of the impact of COVID-19 on Global Neuromonitoring Devices Market
3.Executive Summary
4.Market Overview
4.1.Introduction
4.2.Growth impact forces
4.2.1.Drivers
4.2.2.Restraints
4.2.3.Opportunities
4.3.Market value chain analysis
4.3.1.List of raw material suppliers
4.3.2.List of manufacturers
4.3.3.List of distributors
4.4.Innovation & sustainability matrices
4.4.1.Technology matrix
4.4.2.Regulatory matrix
4.5.Porter’s five forces analysis
4.5.1.Bargaining power of suppliers
4.5.2.Bargaining power of consumers
4.5.3.Threat of substitutes
4.5.4.Threat of new entrants
4.5.5.Competitive rivalry intensity
4.6.PESTLE analysis
4.6.1.Political
4.6.2.Economical
4.6.3.Social
4.6.4.Technological
4.6.5.Environmental
4.7.Impact of COVID-19 on Neuromonitoring devices market
4.7.1.Pre-covid market scenario
4.7.2.Post-covid market scenario
5.Neuromonitoring Devices Market, by Product
5.1.Intracranial Pressure Monitoring
5.1.1.Market size and forecast, by region, 2022-2030
5.1.2.Comparative market share analysis, 2022 & 2030
5.2.Cerebral Oximeter
5.2.1.Market size and forecast, by region, 2022-2030
5.2.2.Comparative market share analysis, 2022 & 2030
5.3.Near Infrared Spectroscopy
5.3.1.Market size and forecast, by region, 2022-2030
5.3.2.Comparative market share analysis, 2022 & 2030
5.4.Speckle Imaging
5.4.1.Market size and forecast, by region, 2022-2030
5.4.2.Comparative market share analysis, 2022 & 2030
5.5.Doppler Ultrasound
5.5.1.Market size and forecast, by region, 2022-2030
5.5.2.Comparative market share analysis, 2022 & 2030
5.6.EEG
5.6.1.Market size and forecast, by region, 2022-2030
5.6.2.Comparative market share analysis, 2022 & 2030
5.7.Fetal/Neonatal Neuro-Monitoring Devices
5.7.1.Market size and forecast, by region, 2022-2030
5.7.2.Comparative market share analysis, 2022 & 2030
5.8.Micro Ultrasound
5.8.1.Market size and forecast, by region, 2022-2030
5.8.2.Comparative market share analysis, 2022 & 2030
5.9.Others
5.9.1.Market size and forecast, by region, 2022-2030
5.9.2.Comparative market share analysis, 2022 & 2030
5.10.Research Dive Exclusive Insights
5.10.1.Market attractiveness
5.10.2.Competition heatmap
6.Neuromonitoring Devices Market, by Region
6.1.North America
6.1.1.U.S.
6.1.2.Market size and forecast, by product , 2022-2030
6.1.3.Canada
6.1.4.Market size and forecast, by product , 2022-2030
6.1.5.Mexico
6.1.6.Market size and forecast, by product , 2022-2030
6.1.7.Research Dive Exclusive Insights
6.1.7.1.Market attractiveness
6.1.7.2.Competition heatmap
6.2.Europe
6.2.1.Germany
6.2.2.Market size and forecast, by product , 2022-2030
6.2.3.UK
6.2.4.Market size and forecast, by product , 2022-2030
6.2.5.France
6.2.6.Market size and forecast, by product , 2022-2030
6.2.7.Spain
6.2.8.Market size and forecast, by product , 2022-2030
6.2.9.Italy
6.2.10.Market size and forecast, by product , 2022-2030
6.2.11.Rest of Europe
6.2.12.Market size and forecast, by product , 2022-2030
6.2.13.Research Dive Exclusive Insights
6.2.13.1.Market attractiveness
6.2.13.2.Competition heatmap
6.3.Asia Pacific
6.3.1.China
6.3.2.Market size and forecast, by product , 2022-2030
6.3.3.Japan
6.3.4.Market size and forecast, by product , 2022-2030
6.3.5.India
6.3.6.Market size and forecast, by product , 2022-2030
6.3.7.Australia
6.3.8.Market size and forecast, by product , 2022-2030
6.3.9.South Korea
6.3.10.Market size and forecast, by product , 2022-2030
6.3.11.Rest of Asia Pacific
6.3.12.Market size and forecast, by product , 2022-2030
6.3.13.Research Dive Exclusive Insights
6.3.13.1.Market attractiveness
6.3.13.2.Competition heatmap
6.4.LAMEA
6.4.1.Brazil
6.4.2.Market size and forecast, by product , 2022-2030
6.4.3.Saudi Arabia
6.4.4.Market size and forecast, by product , 2022-2030
6.4.5.UAE
6.4.6.Market size and forecast, by product , 2022-2030
6.4.7.South Africa
6.4.8.Market size and forecast, by product , 2022-2030
6.4.9.Rest of LAMEA
6.4.10.Market size and forecast, by product , 2022-2030
6.4.11.Research Dive Exclusive Insights
6.4.11.1.Market attractiveness
6.4.11.2.Competition heatmap
7.Competitive Landscape
7.1.Top winning strategies, 2021
7.1.1.By strategy
7.1.2.By year
7.2.Strategic overview
7.3.Market share analysis, 2021
8.Company profiles
8.1.GE Healthcare
8.1.1.Business overview
8.1.2.Financial performance
8.1.3.Product portfolio
8.1.4.Recent strategic moves & developments
8.1.5.SWOT analysis
8.2.Koninklijke Philips N.V.
8.2.1.Business overview
8.2.2.Financial performance
8.2.3.Product portfolio
8.2.4.Recent strategic moves & developments
8.2.5.SWOT analysis
8.3.Medtronic Plc
8.3.1.Business overview
8.3.2.Financial performance
8.3.3.Product portfolio
8.3.4.Recent strategic moves & developments
8.3.5.SWOT analysis
8.4.Nihon Kohden Corporation
8.4.1.Business overview
8.4.2.Financial performance
8.4.3.Product portfolio
8.4.4.Recent strategic moves & developments
8.4.5.SWOT analysis
8.5.Natus Medical Incorporated
8.5.1.Business overview
8.5.2.Financial performance
8.5.3.Product portfolio
8.5.4.Recent strategic moves & developments
8.5.5.SWOT analysis
8.6.Nuvasive, Inc.
8.6.1.Business overview
8.6.2.Financial performance
8.6.3.Product portfolio
8.6.4.Recent strategic moves & developments
8.6.5.SWOT analysis
8.7.Advanced Brain Monitoring, Inc
8.7.1.Business overview
8.7.2.Financial performance
8.7.3.Product portfolio
8.7.4.Recent strategic moves & developments
8.7.5.SWOT analysis
8.8.Intranerve Neuroscience Holdings, LLC
8.8.1.Business overview
8.8.2.Financial performance
8.8.3.Product portfolio
8.8.4.Recent strategic moves & developments
8.8.5.SWOT analysis
8.9.Specialtycare
8.9.1.Business overview
8.9.2.Financial performance
8.9.3.Product portfolio
8.9.4.Recent strategic moves & developments
8.9.5.SWOT analysis
8.10.RIMED Ltd.
8.10.1.Business overview
8.10.2.Financial performance
8.10.3.Product portfolio
8.10.4.Recent strategic moves & developments
8.10.5.SWOT analysis
9.Appendix
9.1.Parent & peer market analysis
9.2.Premium insights from industry experts
9.3.Related reports
* Taxes/Fees, If applicable will be added during checkout. All prices in USD.
Have a question ?
Enquire To BuyNeed to add more ?
Request Customization